Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis

Key Points

• To evaluate the long-term effects of dupilumab treatment on laboratory parameters in adults with moderate-to-severe atopic dermatitis.
• Long-term observational study design
• Participants received dupilumab treatment for up to 5 years
• Laboratory parameters were monitored periodically
• No clinically meaningful changes in laboratory parameters were observed over the treatment duration
• Dupilumab maintained efficacy in managing atopic dermatitis symptoms
• Patients experienced overall stable laboratory outcomes throughout treatment